Fracture risk and zoledronic acid therapy in men with osteoporosis

Steven Boonen, Jean-Yves Reginster, Jean-Marc Kaufman, Kurt Lippuner, Jose Zanchetta, Bente Lomholt Langdahl, Rene Rizzoli, Stanley Lipschitz, Hans Peter Dimai, Richard Witvrouw, Erik Eriksen, Kim Brixen, Luis Russo, Frank Claessens, Philemon Papanastasiou, Oscar Antunez, Guoqin Su, Christina Bucci-Rechtweg, Josef Hruska, Elodie InceraDirk Vanderschueren, Eric Orwoll

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.
OriginalsprogEngelsk
TidsskriftThe New England Journal of Medicine
Vol/bind367
Udgave nummer18
Sider (fra-til)1714-23
Antal sider10
ISSN0028-4793
DOI
StatusUdgivet - 2012

Fingeraftryk

zoledronic acid
Health

Citer dette

Boonen, S., Reginster, J-Y., Kaufman, J-M., Lippuner, K., Zanchetta, J., Langdahl, B. L., ... Orwoll, E. (2012). Fracture risk and zoledronic acid therapy in men with osteoporosis. The New England Journal of Medicine, 367(18), 1714-23. https://doi.org/10.1056/NEJMoa1204061
Boonen, Steven ; Reginster, Jean-Yves ; Kaufman, Jean-Marc ; Lippuner, Kurt ; Zanchetta, Jose ; Langdahl, Bente Lomholt ; Rizzoli, Rene ; Lipschitz, Stanley ; Dimai, Hans Peter ; Witvrouw, Richard ; Eriksen, Erik ; Brixen, Kim ; Russo, Luis ; Claessens, Frank ; Papanastasiou, Philemon ; Antunez, Oscar ; Su, Guoqin ; Bucci-Rechtweg, Christina ; Hruska, Josef ; Incera, Elodie ; Vanderschueren, Dirk ; Orwoll, Eric. / Fracture risk and zoledronic acid therapy in men with osteoporosis. I: The New England Journal of Medicine. 2012 ; Bind 367, Nr. 18. s. 1714-23.
@article{bbbe59e2bbb94bc18ff485236e0171fb,
title = "Fracture risk and zoledronic acid therapy in men with osteoporosis",
abstract = "Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.",
keywords = "Aged, Aged, 80 and over, Analysis of Variance, Bone Density, Bone Density Conservation Agents, Diphosphonates, Double-Blind Method, Humans, Hypogonadism, Imidazoles, Logistic Models, Male, Middle Aged, Osteoporosis, Risk, Spinal Fractures, Testosterone",
author = "Steven Boonen and Jean-Yves Reginster and Jean-Marc Kaufman and Kurt Lippuner and Jose Zanchetta and Langdahl, {Bente Lomholt} and Rene Rizzoli and Stanley Lipschitz and Dimai, {Hans Peter} and Richard Witvrouw and Erik Eriksen and Kim Brixen and Luis Russo and Frank Claessens and Philemon Papanastasiou and Oscar Antunez and Guoqin Su and Christina Bucci-Rechtweg and Josef Hruska and Elodie Incera and Dirk Vanderschueren and Eric Orwoll",
year = "2012",
doi = "10.1056/NEJMoa1204061",
language = "English",
volume = "367",
pages = "1714--23",
journal = "The New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "18",

}

Boonen, S, Reginster, J-Y, Kaufman, J-M, Lippuner, K, Zanchetta, J, Langdahl, BL, Rizzoli, R, Lipschitz, S, Dimai, HP, Witvrouw, R, Eriksen, E, Brixen, K, Russo, L, Claessens, F, Papanastasiou, P, Antunez, O, Su, G, Bucci-Rechtweg, C, Hruska, J, Incera, E, Vanderschueren, D & Orwoll, E 2012, 'Fracture risk and zoledronic acid therapy in men with osteoporosis', The New England Journal of Medicine, bind 367, nr. 18, s. 1714-23. https://doi.org/10.1056/NEJMoa1204061

Fracture risk and zoledronic acid therapy in men with osteoporosis. / Boonen, Steven; Reginster, Jean-Yves; Kaufman, Jean-Marc; Lippuner, Kurt; Zanchetta, Jose; Langdahl, Bente Lomholt; Rizzoli, Rene; Lipschitz, Stanley; Dimai, Hans Peter; Witvrouw, Richard; Eriksen, Erik; Brixen, Kim; Russo, Luis; Claessens, Frank; Papanastasiou, Philemon; Antunez, Oscar; Su, Guoqin; Bucci-Rechtweg, Christina; Hruska, Josef; Incera, Elodie; Vanderschueren, Dirk; Orwoll, Eric.

I: The New England Journal of Medicine, Bind 367, Nr. 18, 2012, s. 1714-23.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Fracture risk and zoledronic acid therapy in men with osteoporosis

AU - Boonen, Steven

AU - Reginster, Jean-Yves

AU - Kaufman, Jean-Marc

AU - Lippuner, Kurt

AU - Zanchetta, Jose

AU - Langdahl, Bente Lomholt

AU - Rizzoli, Rene

AU - Lipschitz, Stanley

AU - Dimai, Hans Peter

AU - Witvrouw, Richard

AU - Eriksen, Erik

AU - Brixen, Kim

AU - Russo, Luis

AU - Claessens, Frank

AU - Papanastasiou, Philemon

AU - Antunez, Oscar

AU - Su, Guoqin

AU - Bucci-Rechtweg, Christina

AU - Hruska, Josef

AU - Incera, Elodie

AU - Vanderschueren, Dirk

AU - Orwoll, Eric

PY - 2012

Y1 - 2012

N2 - Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.

AB - Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.

KW - Aged

KW - Aged, 80 and over

KW - Analysis of Variance

KW - Bone Density

KW - Bone Density Conservation Agents

KW - Diphosphonates

KW - Double-Blind Method

KW - Humans

KW - Hypogonadism

KW - Imidazoles

KW - Logistic Models

KW - Male

KW - Middle Aged

KW - Osteoporosis

KW - Risk

KW - Spinal Fractures

KW - Testosterone

U2 - 10.1056/NEJMoa1204061

DO - 10.1056/NEJMoa1204061

M3 - Journal article

C2 - 23113482

VL - 367

SP - 1714

EP - 1723

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -

Boonen S, Reginster J-Y, Kaufman J-M, Lippuner K, Zanchetta J, Langdahl BL et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. The New England Journal of Medicine. 2012;367(18):1714-23. https://doi.org/10.1056/NEJMoa1204061